Physician profile
Hi S Sim
NPI 1659320505
$10,062.27
in general payments reported to CMS, 2019-2025
47 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,299 · 2020: $629 · 2021: $1,098 · 2022: $1,480 · 2023: $1,477 · 2024: $1,489 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,476 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,476.02 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,336.33 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,031.58 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $970.75 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $858.10 | 2019-2025 | |
| Abbvie INC. | $725.88 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $683.44 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $623.18 | 2019-2025 | Evenity, Prolia, Otezla |
| E.R. Squibb & Sons, L.L.C. | $521.01 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.68 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Grifols USA, LLC | $272.53 | 2019-2025 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $210.84 | 2019-2024 | Austedo Xr |
| Merck Sharp & Dohme LLC | $185.63 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $176.37 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $163.18 | 2020-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $140.87 | 2023-2025 | Rexulti |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hi Sim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.